“VG081821 is to be used as monotherapy for improving movements in early-to-mid stage of PD [Parkinson’s disease]. Later on, as the disease progresses, it can be used in combination with low doses of L-Dopa [levodopa],” said Sanxing Sun, Vimgreen’s president and CEO. “This L-dopa sparing effect may minimize the problem of L-Dopa and prolong the quality of life of PD patients.”
The trial’s main goal is to assess changes in motor symptoms compared with baseline measures (those treatment initiation), using part three of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale. Scientists also will evaluate changes in A2AR levels in circulating blood, because A2AR gene expression, or activity, is known to be high in patients’ blood cells.
UM-Palmitoylethanolamide can slow down Parkinson's disease 2017
Mucuna pruriens in Parkinson’s
Nicotinamide Exacerbates Motor Symptoms of Parkinson’s Disease in Mice
L-carnosine
